Oncology Central

Mechanisms of resistance to EGFR inhibitors in colorectal cancers

0

The EGF receptor (EGFR) is important in the regulation of proliferation, apoptosis and angiogenesis in cancer. EGFR inhibitors have become a mainstay of treatment of metastatic colorectal cancer, in particular KRAS wild-type patients in 50–60% of patients. Despite this many patients do not respond to these agents.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.